Navigation Links
Celator(R) Pharmaceuticals Enrolls First Patient in Its Phase 2 Study of CPX-351 in Acute Myeloid Leukemia in First Relapse
Date:3/10/2009

The study is supported by The Leukemia & Lymphoma Society(R)

PRINCETON, N.J., March 10 /PRNewswire/ -- Celator Pharmaceuticals today announced that the first patient has been treated in its Phase 2 multicenter, randomized, open-label clinical trial of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection versus intensive salvage therapy in adult patients (up to 60 years old) with acute myeloid leukemia in first relapse. As previously announced, the study is being supported through a partnership with The Leukemia & Lymphoma Society (LLS).

The first patient was enrolled by Maureen Cooper, M.D., at St. Francis Hospital in Beech Grove, Indiana. "We are pleased to be participating in this study and eager to collect additional clinical evidence demonstrating the benefit of delivering and maintaining a synergistic ratio of these two widely used drugs for the treatment of AML," said Dr. Cooper.

"CPX-351 represents a unique approach to enhancing the clinical benefit of the two most active drugs used in the treatment of patients with AML," said Jonathan Kolitz, M.D., Director of the Leukemia Service at North Shore University Hospital and lead investigator for the study. "There is no standard of care established for patients in first relapse. We expect that this study will build on the promising results initially obtained in this patient population in the Phase 1 study and provide additional confirmation of the clinical benefit of CPX-351."

The study (Protocol CLTR0308-205) will enroll up to 120 patients between the ages of 18 and 60 who have pathological confirmation of relapsed AML after an initial complete response to prior therapy lasting at least one month. Patients will be randomized (2:1) to receive either CPX-351 (100u/m2; Days 1, 3, 5) or one of several control arm regimens, including high dose cytarabine with or without daunorubicin; conventional "7+3" (cytarabine/daunorubicin reg
'/>"/>

SOURCE Celator Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Frederick R. Appelbaum, M.D. and Ross C. Donehower, M.D. Join Scientific Advisory Board of Celator(R) Pharmaceuticals
2. Celator(R) Pharmaceuticals Presents Phase 1 Results With CPX-351 in Patients With Advanced Leukemia at the American Society of Hematology Meeting
3. Celator(R) Pharmaceuticals To Present at Biotech Showcase 2009
4. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
5. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
6. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
7. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
8. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
9. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
10. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
11. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... Las Vegas, NV (PRWEB) July 25, 2014 ... hosting the one day Online Workshop ‘Consciousness is Power’ ... the globe are invited to attend this life transforming ... their consciousness to a higher level. Few days are ... During this workshop, Mahendra Trivedi and Trivedi Masters™ Dahryn ...
(Date:7/25/2014)... Fort Myers, FL (PRWEB) July 25, 2014 ... Apple iPhones, iPods, and iPads. The app provides a ... preventing painful and potentially dangerous sunburns and skin damage. ... about the sights, sounds, and capabilities of iTanSmart. ... by describing the app as a ‘better organized’ and ...
(Date:7/25/2014)... Silver®Care , for the first time in the United ... kill oral bacteria and airborne bacteria from the bathroom that ... the most common and important device in the prevention of ... to constant contamination by bacteria found in the mouth and ... mouth than anywhere else in the human body, and some ...
(Date:7/24/2014)... 2014 A few weeks have passed ... incredible high jump by Inika McPherson is a feat ... the USATF National Championships hosted the best track and ... McPherson, won US Nationals with the 2nd best jump ... for the biggest height over head jump in history. ...
(Date:7/24/2014)... Voted one of the most reliable online dress suppliers ... providing its new and old customers with the latest ... announced its new collection of high end wedding dresses. ... to the latest fashion trends. Additionally, they are now ... As a matter of fact, high end special occasion ...
Breaking Medicine News(10 mins):Health News:Mahendra Trivedi to Host an Online Workshop ‘Consciousness is Power’ 2Health News:Mahendra Trivedi to Host an Online Workshop ‘Consciousness is Power’ 3Health News:iTanSmart® Suntan App by UV Technologies, LLC Gets a ‘Big Thumbs Up’ from New York Times App Smart Columnist, Kit Eaton 2Health News:iTanSmart® Suntan App by UV Technologies, LLC Gets a ‘Big Thumbs Up’ from New York Times App Smart Columnist, Kit Eaton 3Health News:Silver®Care’s New Silver Antibacterial Toothbrushes Naturally Kill Oral Germs 2Health News:Silver®Care’s New Silver Antibacterial Toothbrushes Naturally Kill Oral Germs 3Health News:Setting A New High Jump World Record In Zensah® Compression 2Health News:Setting A New High Jump World Record In Zensah® Compression 3Health News:BellasDress Helps Brides Get High End Wedding Dresses for Their Romantic Weddings 2
... has succumbed to the accidental 17 overdoses of radiation, almost ... Norris, from Girvan in Ayrshire, was diagnosed with a brain ... Beatson Oncology Centre in Glasgow, Scotland's largest cancer hospital, which ... 20 years. ,Following a series of 17 radiotherapy sessions ...
... drug Velcade has been banned in England because the Government’s ... (NICE) has refused// to fund treatment, according to last night’s ... that Velcade should not be offered on the NHS to ... a course of Velcade has been estimated to cost between ...
... After all these years, mom was right. She knew broccoli ... this good.// ,“Everyone knows broccoli is good for you ... of some types of cancer. We want to know how ... says Janet V. Cross, Ph.D., Assistant Professor of Pathology at ...
... that they have found the brain’s natural antioxidant defense ... radicals//. ,According to the researchers at the ... from the harmful effects of toxic ‘free radicals’ that ... been associated with aging and certain degenerative brain diseases, ...
... novel look at the brains of adults with autism ... people with the developmental disorder may not communicate// with ... people. ,Researchers from the University of Washington’s Autism ... of the Society for Neuroscience on the first study ...
... break the hopes of a team of eminent plastic surgeons ... who are waiting for the// final approval from The Royal ... complete face transplant which would involve the complete replacement of ... is dead. ,Although the hospital had granted ...
Cached Medicine News:Health News:Cancer patient Dies of Massive Radiation Overdose 2Health News:Brain Regions Do Not Communicate Efficiently in Adults with Autism 2
(Date:7/24/2014)... and MENLO PARK, Calif. , July ... DMPI) ("DelMar" "the company") announced today that the company,s board ... from December 31 to June 30. Accordingly, DelMar will file ... Jeffrey Bacha , president and CEO of ... important step in achieving our goal of obtaining a senior ...
(Date:7/24/2014)... ATLANTA , July 24, 2014  Alimera Sciences, ... company that specializes in the research, development and commercialization ... release its second quarter of fiscal year 2014 financial ... 2014. An investor conference call will follow on the ... The conference call will be hosted by Dan ...
(Date:7/24/2014)... 24, 2014  Perrigo Company (NYSE: PRGO ... AB therapeutic equivalent rating from the U.S. Food and ... Application (NDA) for testosterone gel 1.0%. FDA concluded that ... 1% and can be substituted with the full expectation ... safety profile as AndroGel 1% when used under the ...
Breaking Medicine Technology:DelMar Pharmaceuticals Announces Change of Fiscal Year End and Provides Update on Glioblastoma Clinical Trial 2DelMar Pharmaceuticals Announces Change of Fiscal Year End and Provides Update on Glioblastoma Clinical Trial 3Alimera Sciences To Release Second Quarter 2014 Results 2Perrigo Confirms AB Therapeutic Equivalent Rating From The FDA For Its Testosterone Gel 1.0% 2Perrigo Confirms AB Therapeutic Equivalent Rating From The FDA For Its Testosterone Gel 1.0% 3
... 2011 Bacterin International Holdings, Inc. (NYSE ... developer of revolutionary bone graft material and anti-microbial coatings ... first quarter ended March 31, 2011.  Since the beginning ... the number of medical facilities in which its products ...
... Technologies Inc. (OTCBB: MDCE), a children,s healthcare service ... children,s health and wellness center. The City of Dongguan ... of choice to establish the Company,s first flagship pediatric ... chosen because of its progressive economics, recording 10.3% GDP ...
Cached Medicine Technology:Bacterin International Holdings, Inc. Reports First Quarter 2011 Financial Results 2Bacterin International Holdings, Inc. Reports First Quarter 2011 Financial Results 3Bacterin International Holdings, Inc. Reports First Quarter 2011 Financial Results 4Bacterin International Holdings, Inc. Reports First Quarter 2011 Financial Results 5Bacterin International Holdings, Inc. Reports First Quarter 2011 Financial Results 6Bacterin International Holdings, Inc. Reports First Quarter 2011 Financial Results 7Bacterin International Holdings, Inc. Reports First Quarter 2011 Financial Results 8Bacterin International Holdings, Inc. Reports First Quarter 2011 Financial Results 9Medical Care Technologies Inc. Selects Geographical Location for Flagship Children's Health Center 2Medical Care Technologies Inc. Selects Geographical Location for Flagship Children's Health Center 3
The Atria 6100 delivers the highest level of clinical performance while incorporating cutting-edge technology to streamline clinic workflow. It offers timely, high-quality, and accurate ECG results c...
... The new Guidant VASOVIEW® HemoPro™ ... deliver a new level of ... for both the saphenous vein ... cut-and-seal capability, it lets you ...
Patient Monitor...
...
Medicine Products: